A Phase I Trial of the ABCB1 Inhibitor, Oral Valspodar, in Combination With Paclitaxel in Patients With Advanced Solid Tumors.
Paula M FracassoGeorge A FisherSherry A GoodnerJan H BeumerMerrill J EgorinCarole L FearsJonathan D WildiGary J JonesTillman E PearceBranimir I SikicPublished in: American journal of clinical oncology (2023)
Paclitaxel at 70 mg/m2 was administered safely with valspodar. Limited efficacy in hematologic and solid tumors resulted in discontinuation of its clinical development and other transporter inhibitors. Recently, the development of ATP-binding cassette transporter inhibitors has been reconsidered to mitigate resistance to antibody-drug conjugates.